Swedish-based company Empros Pharma has announced positive topline data from its phase 2b trial investigating EMP16, an oral therapy for the treatment of obesity.
Celltrion, one of Korea’s largest biopharma companies, will be Rani’s exclusive supplier of ustekinumab biosimilar, CT-P43, for its oral RT-111 RaniPill program.
Novo Nordisk is expanding its existing collaborative research partnership in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).
Pfizer Inc has started a trial to evaluate its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.
